Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements In Health-related Quality Of Life For Patients Living With Bardet-Biedl Syndrome At ObesityWeek 2021
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, this week presented the first-ever data
Rhythm Pharmaceuticals Presents New Data On Experience Of People Living With Rare Genetic Diseases Of Obesity And Provides Updates On Uncovering Rare Obesity Genetic Testing Program
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today presented the first-ever data on
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
Rhythm Pharma’s Imcivree Wins UK Approval For Obesity, Hunger Control
Britain’s Medicines & Healthcare Products Regulatory Agency (MHRA) has approved Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Imcivree (setmelanotide) for obesity and the control…
Rhythm Pharmaceuticals Completes Submission Of Supplemental New Drug Application To U.S. FDA For IMCIVREE For The Treatment Of Obesity And Control Of Hunger In Bardet-Biedl and Alström Syndromes
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it has completed its
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 8)
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 173 companies reached new 52-week lows.